Changes to Primary Endpoints of Cancer Trials Are Not Being Disclosed in Manuscripts
Changes to primary endpoints of phase 3 cancer trials may be common and underreported, a study suggests.
All articles by Alan P. Lyss, MD
Global Survey Suggests RCC Patients Are Underinformed, Face Obstacles to Care
Results of a global survey highlight areas for improvement in the care of patients with renal cell carcinoma.
Could mRNA Vaccines Help Prevent Recurrence in Pancreatic Cancer?
Pancreatic cancer has proven resistant to immunotherapy in the past, but personalized mRNA vaccines may overcome that problem.
The Cost of Bladder Cancer Care Is Rising. Could Value-Based Care Models Help?
The rising cost of care is having a negative impact on patients with bladder cancer, but a value-based approach to care might provide some relief.
ctDNA Testing in Colorectal Cancer Deemed Promising but Not Ready for Prime Time
Studies suggest that ctDNA testing has prognostic value in colorectal cancer, but more research is needed before it can be used in practice.
SABCS 2022: Trials Show Improved Outcomes in HR+, HER2- Breast Cancer
The CAPItello-291, monarchE, RIGHT Choice, and EMERALD trials have shown favorable outcomes for patients with HR+, HER2- breast cancer.
Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC
Differences in tumor characteristics could explain sex- and race-based disparities in patients with metastatic non-small cell lung cancer.
Up to 10% of Early-Onset mCRC Cases May Be Driven by Undiagnosed IBD
As many as 10% of early-onset metastatic colorectal cancer cases may be attributable to undiagnosed inflammatory bowel disease, a study suggests.
Duration of ET Tied to Benefit in DCIS, but Young Patients May Reject ET
Two new studies shed light on the complexity of preventing subsequent breast cancer events in patients with ductal carcinoma in situ.
Crisis in Oncology Research Demands Urgent Action, Stakeholders Say
At a SITC summit, stakeholders identified administrative, staffing, and other barriers that impede progress in clinical cancer research.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...